Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - Aprea Therapeutics has announced a private placement of common stock and warrants, aiming to raise approximately $5.6 million to support its ongoing clinical studies and general corporate purposes [1][2][3] Group 1: Offering Details - Aprea will sell a total of 6,288,857 shares of common stock (or pre-funded warrants) along with warrants to purchase an equal number of shares, at an effective offering price of $0.89 per share [1][2] - The warrants will have an exercise price of $0.765 per share, exercisable immediately upon issuance, and will expire two years from the effectiveness date of the registration statement [1][2] Group 2: Use of Proceeds - The gross proceeds from the offering are estimated to be around $5.6 million before deducting fees and expenses, which will be used for general corporate purposes and research and development expenses [2] Group 3: Clinical Development Focus - The financing is intended to support the ongoing ACESOT-1 dose-escalation study of APR-1051, a WEE1 kinase inhibitor, with the goal of optimizing dosage and patient population [3] - The addition of more patients to the study is expected to enhance the dataset for safety and early efficacy, potentially leading to significant clinical milestones [3] Group 4: Company Overview - Aprea Therapeutics is focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells [6] - The company's lead programs include APR-1051 and ATRN-119, both of which are in clinical development for solid tumor indications [7]